Comparative analysis of dideoxy sequencing, the KRAS StripAssay and pyrosequencing for detection of KRAS mutation

World Journal of Gastroenterology

Volumn 16, Issue 38, 2010, Pages 4858-4864

  Gao, Jing ^a   Li, Yan Yan ^a   Sun, Ping Nai ^a   Shen, Lin ^a  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Dideoxy sequencing; DNA mutational analysis; KRAS; KRAS StripAssay; Mutation; Pyrosequencing

Indexed keywords

GENOMIC DNA;

ACCURACY; ARTICLE; ASSAY; CHINESE; CODON; COLORECTAL CANCER; CONTROLLED STUDY; EXON; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PYROSEQUENCING; SEQUENCE ANALYSIS;

EID: 78049523620     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i38.4858     Document Type: Article

References (19)

1. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22: 1201-1208
2. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23: 1803-1810
3. Hebbar M, Wacrenier A, Desauw C, Romano O, Cattan S, Triboulet JP, Pruvot FR. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs 2006; 17: 855-857
4. Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 1987; 327: 298-303
5. Pretlow TP, Brasitus TA, Fulton NC, Cheyer C, Kaplan EL. Kras mutations in putative preneoplastic lesions in human colon. J Natl Cancer Inst 1993; 85: 2004-2007
6. Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, Bibeau F, Diebold MD, Rougier P, Ducreux M, Tomasic G, Emile JF, Penault-Llorca F, Laurent-Puig P. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374-379
7. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. Kras mutations and benefit from cetuximab inadvanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765
8. Van Cutsem E, Lang I, D'haens G, Moiseyenko V, Zaluski J, Folprecht G, Tejpar S, Kisker O, Stroh C, Rougier P. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 2008; 26 Suppl: 2
9. Bokemeyer C, Bondarenko I, Hartmann JT, De Braud FG, Volovat C, Nippgen J, Stroh C, Celik I, Koralewski P. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol 2008; 26 Suppl: 4000
10. Tejpar S, Peeters M, Humblet Y, Vermorken JB, De Hertogh G, De Roock W, Nippgen J, von Heydebreck A, Stroh C, Van Cutsem E. Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan(q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data). J Clin Oncol 2008; 26 Suppl: 4001
11. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-2048
12. Wu CM, Tang R, Wang JY, Changchien CR, Hsieh LL. Frequency and spectrum of K-RAS codons 12 and 13 mutations in colorectal adenocarcinomas from Taiwan. Cancer Genet Cytogenet 2005; 158: 55-60
13. Breivik J, Meling GI, Spurkland A, Rognum TO, Gaudernack G. Kras mutation in colorectal cancer: relations to patient age, sex and tumour location. Br J Cancer 1994; 69: 367-371
14. Kislitsin D, Lerner A, Rennert G, Lev Z. Kras mutations in sporadic colorectal tumors in Israel: unusual high frequency of codon 13 mutations and evidence for nonhomogeneous representation of mutation subtypes. Dig Dis Sci 2002; 47: 1073-1079
15. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-532
16. Zalis MG, Vieira FM, Zalcberg-Renault I, Bonamino MH, Ferreira CG, Oliveira S. KRAS mutation profile in colorectal cancer patients in Brazil: A cohort of 989 individuals. J Clin Oncol 2009; 27 Suppl: e15017
17. Poehlmann A, Kuester D, Meyer F, Lippert H, Roessner A, Schneider-Stock R. Kras mutation detection in colorectal cancer using the Pyrosequencing technique. Pathol Res Pract 2007; 203: 489-497
18. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Namgyal C, Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS. Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn 2005; 7: 413-421
19. Huncharek M, Muscat J, Geschwind JF. Kras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis 1999; 20: 1507-1510